Heather Gottlieb, DO
Urogynecology and Reconstructive Pelvic Surgery · Newtown, PANPI 1164402806
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,000 of the $48,028 with a category attached, or 83.3%. Medtronic accounts for 92.7% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2023 at $13,511 and has fallen 62.6% since, to $5,056 in 2025. Among urogynecology and reconstructive pelvic surgery clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $159.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$45K
- AbbVie$714
- Astellas Pharma US Inc$582
- Sumitomo Pharma America, Inc.$482
- 180 Medical, Inc.$192
- Bayer$183
- plus $1K from 30 others
Across 1 payment — averaging $355.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$355
What the payments were for
- Speaking & faculty fees$40,00083%
- Travel & lodging$9752%
- Food & beverage$6,72014%
- Education$3331%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 113 | $44,508 |
| AbbVie(2 entities) | 33 | $714 |
| Astellas Pharma US Inc | 36 | $582 |
| Sumitomo Pharma America, Inc. | 35 | $482 |
| 180 Medical, Inc. | 8 | $192 |
| Bayer | 8 | $183 |
| Coloplast | 9 | $159 |
| Mission Pharmacal Company | 8 | $127 |
| Urovant Sciences Inc | 5 | $116 |
| Boston Scientific | 6 | $103 |
| Dentsply IH AB | 3 | $90 |
| Therapeuticsmd, Inc. | 3 | $64 |
| Olympus America Inc. | 3 | $63 |
| Axonics, Inc. | 2 | $61 |
| Convatec Inc. | 1 | $49 |
| Merck | 3 | $47 |
| Rochester Medical Corporation | 3 | $46 |
| Smith+Nephew | 2 | $43 |
| Ferring Pharmaceuticals Inc. | 3 | $43 |
| Teleflex LLC | 2 | $34 |
| Baxter Healthcare | 1 | $30 |
| Bluewind Medical | 1 | $29 |
| Hollister Incorporated | 1 | $28 |
| Livanova USA, Inc. | 1 | $23 |
| Neotract Inc. | 1 | $22 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $22 |
| Progenics Pharmaceuticals, Inc. | 1 | $22 |
| Laborie Medical Technologies Corp. | 1 | $21 |
| Tolmar Pharmaceuticals, Inc. | 1 | $21 |
| Urogen Pharma, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $18 |
| Mayne Pharma Commercial LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,028 in reported general payments places this provider in the 95th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.
See all urogynecology and reconstructive pelvic surgery providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 287 | $260,772 |
| GemtesaVibegron | 312 | $242,276 |
| ElmironPentosan Polysulfate Sodium | 68 | $112,690 |
| Estradiol | 396 | $25,385 |
| Methenamine Hippurate | 208 | $18,464 |
| Mirabegron ErMirabegron | 12 | $8,323 |
| Amitriptyline Hcl | 296 | $3,782 |
| Hydroxyzine Hcl | 145 | $2,637 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 294 | $2,187 |
| Solifenacin Succinate | 54 | $1,737 |
| Tamsulosin Hcl | 91 | $1,672 |
| Tolterodine Tartrate ErTolterodine Tartrate | 17 | $1,537 |
| Oxybutynin Chloride ErOxybutynin Chloride | 49 | $1,521 |
| Trimethoprim | 13 | $933 |
| Silodosin | 19 | $841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $582 | $260,772287 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $482 | $242,276312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 51 urogynecology and reconstructive pelvic surgery providers in Pennsylvania.
Other urogynecology and reconstructive pelvic surgery in Newtown
- Vincent LucenteAllentown$798K
- Miles MurphyAllentown$54K
- Michael BonidieMechanicsburg$39K
- Lily AryaPhiladelphia$34K
- Julie DroletYork$29K
- Alexander BrusckeQuakertown$24K
- Marc TogliaMedia$22K
- Vani DandoluWilkes Barre$22K
- Luis Espaillat RijoLansdale$15K
- Pamela MoalliPittsburgh$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.